# Subquery 5: Menopausal women, metabolic phenotyping, and diabetes-risk clustering

## Query
**menopausal women metabolic phenotyping clustering diabetes risk subtype identification research studies**

## Short answer
- **Yes, population-specific clustering patterns exist** in menopausal/postmenopausal cohorts (especially for metabolic syndrome and obesity-related metabolic phenotypes).
- **Menopause appears to act as a meaningful stratifier** (biological transition + hormonal changes + age/adiposity interactions), which can change subgroup composition and risk profiles.
- **Direct evidence for “lower silhouette scores specifically due to menopause” is limited/absent** in the retrieved literature; most studies discuss overlap/heterogeneity qualitatively rather than reporting menopause-specific silhouette degradation.

## Findings

### 1) Population-specific clustering patterns in postmenopausal women
- A postmenopausal Korean women study reported **three MetS-related classes** (e.g., diabetic/hypertensive/low-risk type groupings), supporting non-homogeneous metabolic substructure in this population.
  - Source: https://pubmed.ncbi.nlm.nih.gov/39349570/

- Studies in obesity/SLD phenotyping that explicitly combine **diabetes status + sex + menopause** show clinically distinct high-risk strata (e.g., advanced steatotic liver disease risk profiles), indicating menopause can improve clinical phenotyping granularity.
  - Sources:
    - https://onlinelibrary.wiley.com/doi/full/10.1002/oby.23904
    - https://pubmed.ncbi.nlm.nih.gov/37987186/

- Broader women-focused cluster work (symptom/metabolome/phenotype contexts) also shows stage-specific clustering differences across menopausal transition states.
  - Sources:
    - https://pmc.ncbi.nlm.nih.gov/articles/PMC11699220/
    - https://diabetesjournals.org/care/article/33/11/2457/26480/Age-and-Sex-Differences-in-the-Clustering-of

### 2) Does menopause affect metabolic cluster separation?
- **Likely yes, indirectly**: menopause introduces shifts in insulin resistance, lipids, adiposity distribution, and symptom burden, which can both:
  - create clinically meaningful subgrouping (better stratification), and
  - increase overlap between adjacent phenotypes (harder geometric separation).

- In practice, this means menopause is often treated as a **key covariate/stratifier** rather than random noise.

### 3) Evidence on silhouette scores in menopausal cohorts
- From the retrieved set, there is **no strong direct paper-level claim** of: “postmenopausal status causes low silhouette score.”
- The more defensible conclusion is:
  - menopause-associated heterogeneity and overlapping cardio-metabolic profiles provide a **plausible mechanism** for lower internal separation metrics,
  - but most menopause-focused clustering papers do not explicitly report/attribute silhouette outcomes this way.

## Interpretation for thesis/research use
- For menopausal cohorts, prioritize a validation narrative based on:
  1. **clinical interpretability** of clusters,
  2. **outcome separation** (risk, complications, progression),
  3. **stability/replicability**,
  4. and internal metrics (silhouette/CH/DBI) as supportive, not sole, criteria.

- If your observed silhouette is modest in menopausal data, a literature-consistent justification is biological overlap during menopausal transition plus real-world heterogeneity—provided clusters remain clinically useful and reproducible.

## Key references captured from Perplexity session
1. https://pubmed.ncbi.nlm.nih.gov/39349570/
2. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.23904
3. https://pubmed.ncbi.nlm.nih.gov/37987186/
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11699220/
5. https://diabetesjournals.org/care/article/33/11/2457/26480/Age-and-Sex-Differences-in-the-Clustering-of
6. https://www.nature.com/articles/s41591-024-03283-1
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9035269/
